Major Estimate Revision • Apr 24
Consensus revenue estimates increase by 58%, EPS downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$3.65m to AU$5.77m. EPS estimate fell from -AU$0.193 to -AU$0.216 per share. Biotechs industry in Australia expected to see average net income growth of 2.8% next year. Consensus price target up from AU$5.52 to AU$5.72. Share price fell 3.9% to AU$4.73 over the past week. Major Estimate Revision • Mar 17
Consensus revenue estimates increase by 135% The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$1.55m to AU$3.65m. EPS estimate unchanged from -AU$0.19 at last update. Biotechs industry in Australia expected to see average net income growth of 7.9% next year. Consensus price target up from AU$4.88 to AU$5.52. Share price rose 40% to AU$5.60 over the past week. Reported Earnings • Feb 27
First half 2026 earnings released: AU$0.092 loss per share (vs AU$0.086 loss in 1H 2025) First half 2026 results: AU$0.092 loss per share (further deteriorated from AU$0.086 loss in 1H 2025). Net loss: AU$4.62m (loss widened 122% from 1H 2025). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Biotechs industry in Australia. New Risk • Jan 28
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Revenue is less than US$1m (AU$1.1m revenue, or US$737k). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (AU$8.9m net loss in 3 years). 공시 • Jan 21
Tetratherix Limited Confirms Appointment of Maurizio Vecchione as Independent Non-Executive Director Tetratherix Limited has confirmed the appointment of Mr. Maurizio Vecchione as an independent non-executive director. Mr. Vecchione has obtained the required director identification number from the Australian Business Registry Services and has provided a consent to act as a director to the Tetratherix Board. Mr. Vecchione is the Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation and General Partner at AdAstral Funds. He is also named on multiple patents filed in the United States related to material and nano-bio-polymers. Mr. Vecchione has spent the last 30 years at the forefront of biomedicine. He has helped build nine startups and launch more than 50 commercial products spanning health technologies and material sciences. His prior experience includes being Chief Executive Officer at Arrogene Nanotechnology, CompuMED, Trestle and multiple other science companies. Board Change • Jan 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Peter Gray was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. 공시 • Oct 10
Tetratherix Limited, Annual General Meeting, Nov 10, 2025 Tetratherix Limited, Annual General Meeting, Nov 10, 2025. Location: automic group, level 5, 126 phillip street sydney, nsw 2000, Australia Reported Earnings • Sep 02
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: AU$0.36 loss per share (further deteriorated from AU$0.11 loss in FY 2024). Net loss: AU$9.43m (loss widened 269% from FY 2024). Revenue exceeded analyst estimates by 186%. Earnings per share (EPS) missed analyst estimates by 52%. Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Biotechs industry in Australia. New Risk • Jul 18
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Negative equity (-AU$8.4m). Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m (AU$777k revenue, or US$507k). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years). New Risk • Jul 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Negative equity (-AU$8.4m). Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m (AU$777k revenue, or US$502k). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years). New Risk • Jul 07
New major risk - Negative shareholders equity The company has negative equity. Total equity: -AU$8.4m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-AU$8.4m). Revenue is less than US$1m (AU$777k revenue, or US$505k). 공시 • Jun 27
Tetratherix Limited has completed an IPO in the amount of AUD 24.9984 million. Tetratherix Limited has completed an IPO in the amount of AUD 24.9984 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,680,000
Price\Range: AUD 2.88
Discount Per Security: AUD 0.1728 
